NCT02724228
Achondroplasia
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.
All
From 7 Years
No
BMN 111
Phase 2
Interventional
30
2016-01-26
2025-03-25
Oakland, California, United States
Torrance, California, United States
Chicago, Illinois, United States
Baltimore, Maryland, United States
Nashville, Tennessee, United States
Houston, Texas, United States
Parkville, Victoria, Australia
Paris, , France
London, , United Kingdom
*required fields
"*" indicates required fields